Business Information
The group's principal activities are to develop and manufacture products and technologies for the treatment of respiratory, allergy, dermatological and topical conditions. The group focuses its expertise on development-led contract manufacturing in the sterile pharmaceutical, finished dosage-form, outsourcing sector. The products of the group include hydrocarbon aerosols, metered dose inhalers, dry powdered inhalers, metered dose pump sprays and saline aerosols. The group offers it products to blue-chip ethical pharmaceutical companies, branded generic firms and biotechnology groups. On 28-Apr-2003, the group acquired inyx pharma ltd and on 07-Mar-2003 inyx pharma ltd acquired pharmaceutical business assets of miza pharmaceuticals (UK) limited.
|
|
Name |
Title
|
Email
|
| Jack Kachkar | Chmn., CEO | Available | | Colin Hunter | Exec. VP, Chief Scientific Officer, Dir. | Available | | David Zinn | VP - Finance | Available | | Jay Green | Exec. VP, Dir. - Corporate Development | Available | | Marc Couturier | Sr. VP - Global Business Development | Available
|
|
|
Year |
Sales |
Net Income |
| 2005 | 49,565 | (31,009) | | 2004 | 15,699 | (16,942) | | 2003 | 13,099 | (13,392)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
